Overview
NKTR market data
Price History
NKTR price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$9.73 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.24 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -280.8% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $22.50 – $109.00 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $2.6B · P/B 9.57 · P/S 46.78.
Company News
Full Transcript: Nektar Therapeutics Q2 2026 Earnings CallBenzinga · Aug 13, 2026, 10:20 PM
8-K filing — NEKTAR THERAPEUTICS (NKTR)SEC EDGAR · Aug 13, 2026, 8:25 PM
Nektar Therapeutics Q2 EPS $(1.23) Beats $(2.00) Estimate, Sales $10.131M Miss $10.425M EstimateBenzinga · Aug 13, 2026, 8:16 PM
Canaccord Genuity Initiates Coverage On Nektar Therapeutics with Buy Rating, Announces Price Target of $153Benzinga · Jul 22, 2026, 11:12 AM
Nektar Therapeutics Initiates First Two Global Registrational Trials, ZENITH AD-1 and ZENITH AD-2, In Its Phase 3 Program For Rezpegaldesleukin; Initial Phase 3 Topline Data Expected In Mid-2028 With BLA Submission Targeted For 2029Benzinga · Jul 21, 2026, 11:10 AM